Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOVON 151 atezolizumab consolidation in high-risk DLBCL
NL-OMON59549Phase 2Active, not recruiting
- Sponsor
- HOVON
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in diffuse large B-cell lymphoma (DLBCL), sponsored by HOVON. Primary endpoint: Disease-free survival. Started Aug 2018; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NL-OMON59549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59549.